

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
01 October 2020 (01.10.2020)



(10) International Publication Number
WO 2020/197502 A1

(51) International Patent Classification:

C07K 16/28 (2006.01) A61P 17/00 (2006.01)
A61P 37/00 (2006.01) A61K 39/00 (2006.01)
A61P 11/00 (2006.01)

(21) International Application Number:

PCT/SG2020/050170

(22) International Filing Date:

26 March 2020 (26.03.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

10201902713S	26 March 2019 (26.03.2019)	SG
10201905063R	03 June 2019 (03.06.2019)	SG
10201907597W	16 August 2019 (16.08.2019)	SG

(71) Applicants: **ASLAN PHARMACEUTICALS PTE LTD** [SG/SG]; 83 Clemenceau Avenue, UE Square, #12-03, Singapore 239920 (SG). **CSL LIMITED** [AU/AU]; 45 Poplar Road, Parkville, Victoria 3052 (AU).

(72) Inventor: **WARD, Alison**; c/o Aslan Pharmaceuticals PTE LTD, 83 Clemenceau Avenue, UE Square, #12-03, Singapore 239920 (SG).

(74) Agent: **STERLING IP PTE LTD**; 10 Anson Road, International Plaza, #29-09, Singapore 079903 (SG).

(81) Designated States (unless otherwise indicated, for every kind of national protection available):

AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available):


ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(54) Title: TREATMENT EMPLOYING ANTI-IL-13R ANTIBODY OR BINDING FRAGMENT THEREOF

Figure 1 - IgE assay— 3 mg/kg IV



(57) Abstract: The present disclosure provides a method of treatment comprising inhibiting IL-13R with an antibody or binding fragment thereof specific for the receptor with a VH sequence of SEQ ID NO: 51 or a sequence at least 95% identical thereto, and VL sequence of SEQ ID NO: 53 or a sequence at least 95% identical thereto, wherein said antibody or binding fragment is administered at a dose in the range 600mg to 900mg at least once each month, in particular less than twice a month.

WO 2020/197502 A1